Haw Par Corp Ltd H02
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SGD 9.92
- Day Range
- SGD 9.87–9.92
- 52-Week Range
- SGD 9.14–10.22
- Bid/Ask
- SGD 9.89 / SGD 9.91
- Market Cap
- SGD 2.19 Bil
- Volume/Avg
- 49,700 / 94,037
Key Statistics
- Price/Earnings (Normalized)
- 10.07
- Price/Sales
- 9.43
- Dividend Yield (Trailing)
- 4.04%
- Dividend Yield (Forward)
- 4.04%
- Total Yield
- 4.04%
Company Profile
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 595
- Website
- https://www.hawpar.com
Comparables
Valuation
|
Metric
|
H02
|
F17
|
TQ5
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.07 | 13.18 | 10.03 |
Price/Book Value | 0.63 | 0.41 | 0.32 |
Price/Sales | 9.43 | 0.83 | 0.87 |
Price/Cash Flow | 35.28 | 15.72 | 8.78 |
Price/Earnings
H02
F17
TQ5
Financial Strength
|
Metric
|
H02
|
F17
|
TQ5
|
|---|---|---|---|
Quick Ratio | 37.06 | 0.35 | 0.51 |
Current Ratio | 37.28 | 1.53 | 1.09 |
Interest Coverage | 148.52 | 2.01 | 1.24 |
Quick Ratio
H02
F17
TQ5
Profitability
|
Metric
|
H02
|
F17
|
TQ5
|
|---|---|---|---|
Return on Assets (Normalized) | 6.09% | 2.56% | 0.32% |
Return on Equity (Normalized) | 6.28% | 7.34% | 1.29% |
Return on Invested Capital (Normalized) | 6.27% | 3.62% | 1.47% |
Return on Assets
H02
F17
TQ5
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Dlckgxjstl | Jtsb | $808.7 Bil | |||
| Johnson & Johnson
JNJ
| Xvrjnrpw | Tjvyq | $352.5 Bil | |||
| Merck & Co Inc
MRK
| Dnljpcvch | Ygvv | $320.3 Bil | |||
| AbbVie Inc
ABBV
| Vtyzvczmr | Lnn | $295.3 Bil | |||
| AstraZeneca PLC ADR
AZN
| Mcnmdfcmf | Vrt | $239.2 Bil | |||
| Novartis AG ADR
NVS
| Fwkqsbvp | Mnfc | $218.9 Bil | |||
| Roche Holding AG ADR
RHHBY
| Mxpzqmslpl | Nfhp | $218.3 Bil | |||
| Amgen Inc
AMGN
| Srybfwqzr | Jwn | $166.8 Bil | |||
| Pfizer Inc
PFE
| Cmqxsddjv | Zts | $157.0 Bil | |||
| Sanofi SA ADR
SNY
| Pqdzvxt | Ggdf | $122.8 Bil |